+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis



Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis



Clinicoeconomics and Outcomes Research 8: 177-186



Although previous studies have demonstrated the clinical benefits of dalfampridine extended release (D-ER) tablets in patients with multiple sclerosis (MS), there are limited real-world data on D-ER utilization and associated outcomes in patients with MS. The objective of this study was to evaluate treatment patterns, budget impact, and health care resource utilization (HRU) associated with D-ER use in a real-world setting. A retrospective claims database analysis was conducted using the HealthCore Integrated Research Database(SM). Adherence (measured by medication possession ratio, or [MPR]) and persistence (measured by days between initial D-ER claim and discontinuation or end of follow-up) were evaluated over 1-year follow-up. Budget impact was calculated as cost per member per month (PMPM) over the available follow-up period. D-ER and control cohorts were propensity-score matched on baseline demographics, comorbidities, and MS-related resource utilization to compare walking-impairment-related HRU over follow-up. Of the 2,138 MS patients identified, 1,200 were not treated with D-ER (control) and 938 were treated with D-ER. Patients were aged 51 years on average and 74% female. Approximately 82.6% of D-ER patients were adherent (MPR >80%). The estimated budget impact range of D-ER was $0.014-$0.026 PMPM. Propensity-score-matched D-ER and controls yielded 479 patients in each cohort. Postmatching comparison showed that the D-ER cohort was associated with fewer physician (21.5% vs 62.4%, P<0.0001) and other outpatient visits (22.8% vs 51.4%, P<0.0001) over the 12-month follow-up. Changes in HRU from follow-up to baseline were lower in the D-ER cohort for metrics including walking-impairment-related hospitalizations and emergency department visits. The majority of D-ER patients were adherent to treatment. D-ER utilization was associated with fewer walking-impairment-related physician and outpatient visits, with lower HRU increase over time. The budget impact of D-ER was low.

(PDF emailed within 0-6 h: $19.90)

Accession: 059169769

Download citation: RISBibTeXText

PMID: 27274292

DOI: 10.2147/CEOR.S99750


Related references

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis. Therapeutics and Clinical Risk Management 11: 1-7, 2015

Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. Journal of Managed Care and Specialty Pharmacy 23(7): 771-780, 2018

Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. Bmc Psychiatry 17(1): 222, 2018

Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis. Open Access Rheumatology 10: 103-111, 2018

Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery. Clinicoeconomics and Outcomes Research 4: 169-176, 2012

Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. Canadian Journal of Cardiology 26(7): E229-E235, 2010

Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Current Medical Research and Opinion 30(8): 1461-1471, 2015

Antibiotics Treatment Patterns As A Costs And Resource Utilization Predictor Among Patients Submitted To Bariatric Surgery: Analysis of A Large Health Insurance Claims Database. Value in Health 20(9): A892-A893, 2017

Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. Journal of Dermatological Treatment 29(8): 747-753, 2018

Health Care Utilization and Costs of Multiple Sclerosis Patients in the Netherlands: A Health Care Claims Database Study. Value in Health 20(9): A719-A720, 2017

Association Between Financial Incentives for Regional Care Coordination and Health Care Resource Utilization Among Older Patients after Femoral Neck Fracture Surgery: A Retrospective Cohort Study Using a Claims Database. Population Health Management 21(4): 331-337, 2017

Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis. Advances in Therapy 34(11): 2436-2451, 2017

Health care resource utilization following initiation of a triptan: a retrospective claims analysis. Journal of Managed Care and Specialty Pharmacy 20(4): 368-375, 2014

AB0526Patient Characteristics, Treatment Patterns, Resource Utilization and Costs of Sjogren's Syndrome Using A U.S. Managed Care Prescription Claims Database. Annals of the Rheumatic Diseases 74(Suppl 2): 1076.1-1076, 2015

Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clinical Therapeutics 30(2): 358-371, 2008